Keyphrases
13C Pyruvate
26%
64Cu-DOTATATE
26%
Atherosclerotic Plaque
17%
Cancer Patients
60%
Canine Cancer
26%
Carotid Endarterectomy
26%
Clinical PET
26%
Computed Tomography
26%
Cross-calibration
26%
F-18
26%
First-in-human
29%
First-in-human Study
30%
Fluorodeoxyglucose
26%
Glycolysis
26%
HyperPET
26%
Image Artifacts
26%
In Cancer
32%
In Situ Breast Cancer
26%
Intravenous Contrast
26%
Intravenous Contrast Agents
17%
Lactate
26%
Long-term Reproducibility
26%
Long-term Stability
26%
Lymph Node
26%
Magnetic Resonance Spectroscopy
26%
Molecular Imaging
17%
MR-based Attenuation Correction
26%
Neuroendocrine Tumor
26%
Non-culprit Lesion
53%
Open-label Trial
26%
PET Attenuation Correction
26%
PET Image
17%
PET Scan
20%
PET-MRI
37%
Phantom Measurements
26%
Plaque Composition
17%
Positron Emission Tomography
53%
Positron Emission Tomography-computed Tomography (PET-CT)
37%
Radioactive Seed Localization
80%
Renal Cell Carcinoma
26%
Siemens
26%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
26%
Standardized Uptake Value
18%
Surgical Procedures
19%
Total-body PET/CT
34%
Von Hippel-Lindau Disease
26%
Vulnerable Atherosclerotic Plaque
26%
Wire Localization
26%
Medicine and Dentistry
Atherosclerosis
26%
Breast Cancer
33%
Carbon 13
21%
Carotid Endarterectomy
20%
Clear Cell Renal Cell Carcinoma
26%
Copper 64
26%
Deoxyglucose
26%
Fluorine-18
21%
Human Study
30%
Lactic Acid
26%
Lymph Node
26%
Malignant Neoplasm
80%
Molecular Imaging
17%
Neoplasm
18%
Neuroendocrine Tumor
26%
NMR Spectroscopy
26%
Open-Label Trial
26%
Polyethylene Terephthalate
100%
positron emission tomographic scan
62%
Positron Emission Tomography-Computed Tomography
40%
Pyruvic Acid
26%
Radioactive Seed
80%
Surgery
17%
Surgical Technique
20%
Urokinase Receptor
26%
Von Hippel-Lindau Disease
26%
Whole Body PET
32%